What do the following board members have in common when it comes to specific skills and experiences
Rob B Thomas AO, BEc, MSAA, SF Fin, FAICD, FRSN
licensing and commercialisation of innovation; strategy and risk management; occupational health & safety (“OH&S”
; and remuneration.
He has also had significant experience with US based companies as they progress from research to commercialisation
Jacinth (Jackie) K Fairley BSc, BVSc (Hons), MBA, GAICD, FTSE
In particular, Dr Fairley has significant leadership skills in
licensing and commercialisation of innovation; business development
Zita Peach BSc, GAICD, FAMI
substantial expertise as a leader in
licensing and commercialisation of innovation; sales, marketing and business development
The other new directors have not been there long enough to categorise them
I bring this up because there are now 3 products in the market place that are generating very little revenue for the company
Let's start with the condom. Officially it has been licensed in multiple countries including Australia, Canada, New Zealand, and Japan and in parts of the EU. I remember when it became available for sale in Australia, pharmacies and all Woolworths supermarkets stocked it. Ansell were the licensee. However in New Zealand even though there was a distributor and the regulatory body of this country had approved it for sale, the condom was never ever sold in this jurisdiction. Fast forward to Canada (approved and marketed there for a year or so), and guess what no where to be found currently. I really do not know what is happening in Europe
So there you have it. As far as I can make out our condom is only currently available in Japan
In early 2020 I asked our illustrious leader, why has not the condom been available for sale in Australia, Canada, and New Zealand. Her reply was..... really. She then went on to say it was the responsibility of the licensee to provide and market the product.
As of now this condom has not been available in Australia for more than 4 years, Canada almost 3 years, and New Zealand
ever
GO BACK TO THE SPECIFIC SKILL SETS AND EXPERIENCES IN LICENSING AND COMMERCIALISATION OF PRODUCTS!!!
Next on the list is Vivagel
What a debacle this has been. The market is more than 1.75 billion US$. What are we generating in revenue for this.
10% is 175 million
1% is 17.5 million
0.1% is 1.75 million
If we are generating half of 0.1% of 1.75 million US$, I think this would be generous
Let us look at the US market and what we know. Starpharma crossed all the t's and dotted all the i's and had a SPA and were in continual communications with FDA. In December of 2018 a licensee was appointed with 20 million $US upfront (equivalent of around $32 million AU) and milestone payments and royalties totalling $US81 million (AUD 126 in today's market) on approval of NDA by the regulatory body. A few days later the FDA said no to the application. Starpharma have never said the FDA issued a complete response letter (CRL). After this shocking knock back I was in contact with the CEO. She indicated to me, at the last minute those working on the NDA were replaced with others. A conspiracy theory. Who knows. We certainly don't. In the last almost 4 years, Starpharma have stated there were two avenues to go down. One was a quick trial and the other was through arbitration and formal review process.
Almost 4 years later we still do not know what is going on. Which brings me to my next point. Our famous licensee Mundipharma. How many countries are we licensed in. How many countries are we selling in. Is it in brick and mortar stores, is it being marketed on line. Mundipharma have failed dismally in promoting vivagel globally. Who negotiated terms and conditions with them
GO BACK TO THE SPECIFIC SKILL SETS AND EXPERIENCES IN LICENSING AND COMMERCIALISATION OF PRODUCTS!!!
Finally Viraleze
I feel if this product was not taken off the shelves in UK more than a year ago, it could have generated 100's of millions of dollars for us. However when it comes to marketing online and selling product Starpharma are abysmal at this. Politics and 3rd parties interfered in what was to be a cash cow
Cannot find fault in the board for what happened here
Conspiracy theories or not........there was foul play a plenty. We do not have it approved in Australia. Why not......you tell me
Okay enough of the "commercialised" stuff
Our dendrimer enhanced products is where the real money is
Phase 2 in house human trials
Dep Docetaxel monotherapy for multiple indications
Dep Docetaxel in combination with Nintedanib
Dep Docetaxel in combination with Gemcitabine
Dep Cabazitaxel monotherapy for multiple indications
Dep Irinotecan monotherapy for multiple indications
Dep Irinotecan in combination with folfiri
and soon to be Dep Gemcitabine in phase 1/2 trials
Starpharma began the combination trial with Nintedanib some time ago without any published results from my recollection. The company must have completed this study. Starpharma began the combination trial with Gemcitabine way after the Nintedanib combination trial and gave us a hint just recently of one case study. I believe the Dep Docetaxel monotherapy trial is now complete and the company in my opinion is just sitting on these results biding it's time as to when to release this data
The same would be apply to the off patent drug AstraZeneca gave Starpharma to improve. I certainly believe this pre clinical trial is now finished and Starpharma is negotiating with AstraZeneca for a way forward for this new formulation. I do not think AstraZeneca will walk away and let Starpharma develop it themselves or get a third party involved
Then there is the 3 radiotherapeutic drugs ready to go into human trials. Just a matter of time before they have signed on a new partner in my opinion
Our partnerships in oncology are certainly very strong with 3 of the known top ten pharmaceutical companies
Our technology is one of click and play
How much Starpharma are holding back on is debateable. I believe in the company certainly
However as many have said.........we need better communication between them and us
Stay tuned
The status quo is about to be turned on it's head in my opinion
